ArticleGenome research1999
Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR.
Article in Genome research, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 65 citations in OpenAlex.
- Identification of SNPs associated with muscle yield and quality traits using allelic-imbalance analyses of pooled RNA-Seq samples in rainbow trout.BMC genomics · 2017Article
- Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective.Cellular and molecular gastroenterology and hepatology · 2017Review
- Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.Acta neuropathologica · 2014Article
- Article
- Cervical carcinoma-associated fibroblasts are DNA diploid and do not show evidence for somatic genetic alterations.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.Human mutation · 2011Article
- Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.World journal of gastroenterology · 2010Review
- Passenger mutations as a marker of clonal cell lineages in emerging neoplasia.Seminars in cancer biology · 2010Review
- Deletion at fragile sites is a common and early event in Barrett's esophagus.Molecular cancer research : MCR · 2010Article
- Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.Cancer prevention research (Philadelphia, Pa.) · 2008Article
- Article
- Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system.The Journal of molecular diagnostics : JMD · 2007Article
- NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.PLoS medicine · 2007Article
- FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.Blood · 2006Article
- Double inactivation of NF1 in tibial pseudarthrosis.American journal of human genetics · 2006Article
- Direct amplification of single-stranded DNA for pyrosequencing using linear-after-the-exponential (LATE)-PCR.Analytical biochemistry · 2006Article
- Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer.World journal of gastroenterology · 2005Review
- Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo.Oncogene · 2004Article
- Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.Journal of the National Cancer Institute · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Loss of heterozygosity (LOH) is a common genetic lesion found in many human neoplasms. Extending investigation of LOH to large-scale clinical and public health science studies has proven difficult because of the small size and cellular and genetic heterogeneity of human neoplasms, in addition to the challenges associated with increasing throughput. Our approach to LOH analysis was developed using clinical biopsy samples from patients with Barrett's esophagus (BE) and uses flow cytometric cell sorting to increase sample purity, whole genome amplification to increase sample amount, and automated fluorescent genotyping to increase sample throughput. This approach allows LOH assessment at 20 loci in DNA extracted from 1000 flow-purified cells while maintaining accurate and reproducible allele ratios compared with the standard method of using genomic DNA. This method of analysis should allow accurate, reproducible determination of allele ratios in a variety of human tumors and premalignant conditions.
Indexed as
Identifiers
10330128PMC310769W1923803423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.